KMT2A and acute myeloid leukemia: Combinations of CDKI-73 with JQ1 or iBET-151 resulted in the synergistic reduction in cell viability, improved median EFS (Event-Free Survival), as compared to monotherapies against infant ALL and adult AML PDX models harboring the MLL-rearrangement (MLL-r) gene.